The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessAbstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,801–2,900 of 15,747
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 46
Inchingolo, A. D., Inchingolo, A. M., Bordea, I. R., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G. M., Isacco, C. G., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040793 · Cited by 64
Batch‐dependent safety of the BNT162b2 mRNA COVID‐19 vaccine
Schmeling, M., Manniche, V., & Hansen, P. R. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.13998 · Cited by 41
Frara, S., Loli, P., Allora, A., Santini, C., di Filippo, L., Mortini, P., Fleseriu, M., & Giustina, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09672-y · Cited by 44
Kemp, F., Proverbio, D., Aalto, A., Mombaerts, L., d’Hérouël, A. F., Husch, A., Ley, C., Gonçalves, J. M., Skupin, A., & Magni, S. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110874 · Cited by 49
Rowntree, L. C., Petersen, J., Juno, J. A., Chaurasia, P., Wragg, K. M., Koutsakos, M., Hensen, L., Wheatley, A. K., Kent, S. J., Rossjohn, J., et al. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12482 · Cited by 40
“International research efforts have led to the development of successful COVID-19 vaccine candidates, which have proven to be safe and effective in phase 2/3 clinical trials, especially against severe hospitalization and fatal disease outcomes.(2,3) While rolling out the vaccination programs globally, it is still impo…”
BackgroundSadeghi, S., Kalantari, Y., Shokri, S., Fallahpour, M., Nafissi, N., Goodarzi, A., & Valizadeh, R. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105196 · Cited by 45
Law, J. L., Logan, M. R., Joyce, M., Landi, A., Hockman, D. J., Crawford, K., Johnson, J., LaChance, G., Saffran, H. A., Shields, J. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.081 · Cited by 45
Rohde, C. M., Lindemann, C., Giovanelli, M. A., Sellers, R. S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A. B., Chervona, Y., Muik, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020417 · Cited by 49
“This was confirmed in Phase 3 clinical trial, with generally mild to moderate fever (body temperature ≥ 38 ◦C) reported in up to 16% of BNT162b2 recipients, mainly after the second dose [39].”
BackgroundSelf-citationPratesi, F., Caruso, T., Testa, D., Tarpanelli, T., Gentili, A., Gioè, D., & Migliorini, P. (2021) · Vaccines · doi:10.3390/vaccines9060672 · Cited by 37
Ferretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
“Patients with immunodeficiency and autoimmune diseases were included in the trial with BNT162b2 but the data have not been published yet (4, 34).”
BackgroundResultInfluentialPaun, R. A., Jurchuk, S., & Tabrizian, M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10601 · Cited by 57
“66,67 These types of nucleic acid delivery systems can also be applied to several other disease areas, including for the treatment of cancer.”
BackgroundDeyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42
Citu, I. M., Cîtu, C., Gorun, F. I., Sas, I., Tomescu, L. C., Neamțu, R., Motoc, A., Gorun, O. M., Burlea, B., Bratosin, F., et al. (2022) · Viruses · doi:10.3390/v14020307 · Cited by 38
“It seems improbable that the difference in antibody levels reported in this research between pregnant and non-pregnant women after immunization is due to the groups’ significant age difference of 16 months, as other studies suggest [23].”
ResultShaker, M. S., Abrams, E. M., & Greenhawt, M. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.02.054 · Cited by 39
Linardou, H., Spanakis, N., Koliou, G.-A., Christopoulou, A. N., Karageorgopoulou, S., Alevra, N., Vagionas, A., Tsoukalas, N., Sgourou, S., Fountzilas, E., et al. (2021) · Cancers · doi:10.3390/cancers13184621 · Cited by 42
“In vaccine pivotal trials, there were no differences in efficacy depending on age, sex, or presence of comorbidities [14].”
BackgroundMazur, M., Duś‐Ilnicka, I., Jedliński, M., Ndokaj, A., Janiszewska‐Olszowska, J., Ardan, R., Radwan‐Oczko, M., Guerra, F., Luzzi, V., Vozza, I., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094965 · Cited by 39
“Initial safety and efficacy for BNT162b2 (Pfizer and BioNtech) has been demonstrated in a study on a total of 43,584 participants randomized to vaccine and placebo [5].”
BackgroundLin, M., Yin, Y., Zhao, X., Wang, C., Zhu, X., Zhan, L., Chen, L., Wang, S., Lin, X. M., Zhang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56302-1 · Cited by 46
Walls, A., Miranda, M. C., Pham, M. N., Schäfer, A., Greaney, A. J., Arunachalam, P. S., Navarro, M., Tortorici, M. A., Rogers, K. A., O'Connor, M. A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.15.435528 · Cited by 19
Angkasekwinai, N., Sewatanon, J., Niyomnaitham, S., Phumiamorn, S., Sukapirom, K., Sapsutthipas, S., Sirijatuphat, R., Wittawatmongkol, O., Senawong, S., Mahasirimongkol, S., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100153 · Cited by 41
Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects
Bafaloukos, D. I., Gazouli, I., Koutserimpas, C., & Samonis, G. (2023) · Vaccines · doi:10.3390/vaccines11030636 · Cited by 49
The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers
Abo-Leyah, H., Gallant, S., Cassidy, D. M., Giam, Y. H., Killick, J., Marshall, B., Hay, G., Snowdon, C., Hothersall, E. J., Pembridge, T., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00080-2021 · Cited by 43
Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness
Li, K. Q., Shi, X., Miao, W., & Tchetgen, E. T. (2023) · Journal of the American Statistical Association · doi:10.1080/01621459.2023.2220935 · Cited by 54
Adam, M., Gameraddin, M. B., Alelyani, M., Alshahrani, M. Y., Gareeballah, A., Ahmad, I., Azzawi, A., Komit, B., & Musa, A. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s330689 · Cited by 38
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 48
Yang, Z., Wang, Y., Jin, Y., Zhu, Y., Wu, Y., Li, C., Kong, Y., Song, W., Tian, X., Zhan, W., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00810-1 · Cited by 37
COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases
Lechien, J. R., Diallo, A. O. K., Dachy, B., et al. (2021) · Ear Nose & Throat Journal · doi:10.1177/01455613211033125 · Cited by 38
“The most prevalent post-vaccine symptoms include fatigue, headache, arthralgia, myalgia, and fever, 7 but there is no mention of olfactory or gustatory dysfunction in studies.”
BackgroundThe COVID-19 Citizen Science Study: Protocol for a Longitudinal Digital Health Cohort Study
Beatty, A. L., Peyser, N. D., Butcher, X., Carton, T. W., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2021) · JMIR Research Protocols · doi:10.2196/28169 · Cited by 34
Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
Chavda, V. P., Balar, P. C., Vaghela, D. A., Solanki, H., Vaishnav, A., Hala, V., & Vora, L. K. (2023) · Vaccines · doi:10.3390/vaccines11010160 · Cited by 40
Viral vector and nucleic acid vaccines against COVID-19: A narrative review
Khoshnood, S., Ghanavati, R., Shirani, M., Ghahramanpour, H., Sholeh, M., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.984536 · Cited by 41
“The safety profile of the vaccine included short-term, mild-to-moderate pain at the site of injection, fatigue, and headache (Polack et al., 2020).”
BackgroundHoffmann, M. A., Wieler, H. J., Enders, P., Buchholz, H., & Plachter, B. (2021) · Vaccines · doi:10.3390/vaccines9080911 · Cited by 41
“The pre-approval study for the BNT162b2 mRNA COVID-19 vaccine [7] lists age populations with regard to local or systemic vaccine reactions that allow for a sharpness of separation at 55 and 65 years.”
BackgroundMethodInfluentialLee, P., Kim, C.-U., Seo, S. H., & Kim, D. (2021) · Immune Network · doi:10.4110/in.2021.21.e4 · Cited by 42
Ben‐Tov, A., Banon, T., Chodick, G., Kariv, R., Assa, A., & Gazit, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.076 · Cited by 38
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
Montoya, J. G., Adams, A. E., Bonetti, V., Deng, S., Link, N. A., Pertsch, S., Olson, K., Li, M., Dillon, E. C., & Frosch, D. L. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01162-21 · Cited by 41
Serological response to COVID-19 vaccination in patients with cancer older than 80 years
Iacono, D., Cerbone, L., Palombi, L., Cavalieri, E., Sperduti, I., Cocchiara, R. A., Mariani, B., Parisi, G., & Garufi, C. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.06.002 · Cited by 35
“This pivotal study excluded patients receiving immunosuppressive therapy and those diagnosed with an immunosuppressive condition [1].”
Cacciottolo, M., Nice, J. B., Li, Y., LeClaire, M. J., Twaddle, R., Mora, C. L., Adachi, S. Y., Chin, E. R., Young, M., Angeles, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00503-23 · Cited by 39
“SARS-CoV-2 has been the promoter of scientific advancement in the vaccinology field, resulting in the rapid development and approval of new mRNA-based vaccines from Moderna and Pfizer (4, 5) and the subsequent approval of protein-based vaccines from Novavax (6, 7).”
BackgroundWang, P., Lau, S.-Y., Deng, S., Chen, P., Mok, B. W.-Y., Zhang, J., Lee, A. C.-Y., Chan, K., Tam, R. C.-Y., Xu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23166-0 · Cited by 37
A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety
Bae, S., Yoo, S., Lee, J. S., Park, H., Kwon, S. P., Jin, H., Park, S., Lee, Y., Bang, Y., Roh, G., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.012 · Cited by 65
“The weight of immune organs, including the spleen and LNs, was slightly increased in both LNP S050L (G2) and Con-LNP (G3) groups compared to that in the saline group (G1), suggesting that the R/L mRNA ⊂ LNPs might stimulate immune responses [1,2,44].”
BackgroundA fluorinated ionizable lipid improves the mRNA delivery efficiency of lipid nanoparticles
Huo, H., Cheng, X., Xu, J., Lin, J., Chen, N., & Lu, X. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00516j · Cited by 40
Bayart, J., Morimont, L., Closset, M., Wieërs, G., Roy, T., Gérin, V., Elsen, M., Eucher, C., Eeckhoudt, S. V., Ausselet, N., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9061340 · Cited by 44
“Pfizer-BioNTech; Puurs, Belgium and Mainz, Germany) conferred a protection of 95% against coronavirus disease 2019 (COVID-19) in a large and multinational clinical trial [2].”
BackgroundResultInfluentialCOVID-19 and obesity: fighting two pandemics with intermittent fasting
Ealey, K. N., Phillips, J. C., & Sung, H. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.06.004 · Cited by 42
“According to published clinical trial results, Pfizer-BioNTech’s COVID-19 vaccine was 95% effective in preventing COVID-19 disease, including in people with obesity (BMI ≥30 kg/m(2)), who comprised one-third of participants in the clinical trial [42].”
ResultLind, M. L., Dorión, M., Houde, A. J., Lansing, M., Lapidus, S., Thomas, R., Yildirim, I. B., Omer, S. B., Schulz, W. L., Andrews, J. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40750-8 · Cited by 42
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 42
Xu, Y., Cui, H., Pang, K., Li, G., Gong, F., Dong, S., Wang, B., & Li, B. (2026) · Cell · doi:10.1016/j.cell.2026.01.012 · Cited by 83
Promising Technologies in the Field of Helminth Vaccines
Perera, D. J., & Ndao, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711650 · Cited by 46
Angel-Korman, A., Peres, E., Bryk, G., Lustig, Y., Indenbaum, V., Amit, S., Rapoport, V., Katzir, Z., Yagil, Y., Iaina, N. L., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab206 · Cited by 45
“This time period was similar to the one used in the original study that led to vaccine authorization [1] and significantly longer than the median time in other published studies (30–58 days) [20–22].”
BackgroundResultRiccio, M. D., Boccalini, S., Rigon, L., Biamonte, M. A., Albora, G., Giorgetti, D., Bonanni, P., & Bechini, A. (2021) · Vaccines · doi:10.3390/vaccines9060633 · Cited by 41
Zhang, S., Ponce, J., Zhang, Z., Lin, G., & Karniadakis, G. E. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009334 · Cited by 42
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac404 · Cited by 44
“The messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer BioNTech) vaccines have shown high efficacy in preventing COVID-19 in healthy individuals [5, 6].”
BackgroundSantosa, A., Xu, C., Arkachaisri, T., Kong, K. O., Lateef, A., Lee, T. H., Leong, K. H., Low, A. H. L., Sriranganathan, M. K., Tan, T. C., et al. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14107 · Cited by 38
Choueiri, T. K., Labaki, C., Bakouny, Z., Hsu, C., Schmidt, A. L., Lopes, G. D. L., Jr., Hwang, C., Singh, S. R. K., Jani, C., Weissmann, L. B., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100445 · Cited by 39
Guo, W., Duan, K., Zhang, Y., Yuan, Z., Zhang, Y., Wang, Z., Zhao, D., Zhang, H., Xie, Z., Li, X., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101010 · Cited by 38
Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination
Fueyo‐Rodríguez, O., Valente-Acosta, B., Jiménez-Soto, R., et al. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242220 · Cited by 38
Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19
Lindner, H. A., Velásquez, S. Y., Thiel, M., & Kirschning, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.602130 · Cited by 41
Mason, T., Whitston, M., Hodgson, J., Watkinson, R., Lau, Y., Abdulrazeg, O., & Sutton, M. (2021) · BMC Medicine · doi:10.1186/s12916-021-02149-4 · Cited by 38
“These estimates are also comparable to estimates of vaccine effectiveness against documented infection in working-age adults in England (70% after one dose, 85% 7 days after second dose) [9] and to all-age results from a randomised controlled trial (52% rising to 95%) [3].”
BackgroundResultLipid-based nanoparticles and RNA as innovative neuro-therapeutics
Tsakiri, M., Zivko, C., Demetzos, C., & Mahairaki, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900610 · Cited by 41
“Their safety is well-established due to the recent approval and massive administration of Pfizer/BioNTech and Moderna mRNA vaccines (Polack et al., 2020; Baden et al., 2021).”
BackgroundAvner, M., Orevi, M., Caplan, N., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05278-3 · Cited by 38
McDade, T. W., Demonbreun, A. R., Sancilio, A., Mustanski, B. S., D’Aquila, R. T., & McNally, E. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-96879-3 · Cited by 40
Collatuzzo, G., Visci, G., Violante, F., Porru, S., Spiteri, G., Monaco, M., Fillon, F. L., Negro, C., Janke, C., Castelletti, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986085 · Cited by 38
“When interpreting the results on vaccines immunogenicity, geographical and ethnical aspects should be taken into account (44): the vaccines efficacy has been reported to be impaired by locally circulating variants; also, different level of efficacy of Comirnaty have been described by ethnicity.”
BackgroundMinimizing the ratio of ionizable lipid in lipid nanoparticles for in vivo base editing
Chen, Q., Wang, X., Zhang, Y., Tian, M., Duan, J., Zhang, Y., & Yin, H. (2024) · National Science Review · doi:10.1093/nsr/nwae135 · Cited by 42
Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives
Chiappalupi, S., Salvadori, L., Vukašinović, A., Donato, R., Sorci, G., & Riuzzi, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119251 · Cited by 40
A Highly Potent SARS-CoV-2 Blocking Lectin Protein
Ahan, R. E., Hanifehnezhad, A., Kehribar, E. Ş., Oğuzoğlu, T. Ç., Földes, K., Özçelik, C. E., Filazi, N., Öztop, S., Palaz, F., Önder, S., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00006 · Cited by 37
Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19
Capodice, J. L., & Chubak, B. M. (2021) · Chinese Medicine · doi:10.1186/s13020-020-00419-6 · Cited by 41
The hindrances to perform the COVID-19 vaccination in Brazil
Boschiero, M. N., Palamim, C. V. C., & Marson, F. A. L. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1955607 · Cited by 45
“S (Johnson/JanssenTM) and CoronaVac´s (SinovacTM) COVID-19 vaccines.13 The characteristics of the approved vaccines are synthetized in Table 1.9,14–22 Unfortunately, only a few vaccines have a phase III clinical trial already published, such as BNT162b2 (Pfizer/BioNtechTM), followed by mRNA-1273 (Moderna’sTM), AZD1222…”
BackgroundInfluentialMyocarditis following mRNA vaccination against SARS-CoV-2, a case series
King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Pardo, L. C., & Petersen, J. W. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100042 · Cited by 39
“Phase 3 multicenter randomized controlled trials showed 94 – 95% efficacy in prevention of severe COVID-19 [1,2].”
InfluentialClocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic
Sengupta, S., Ince, L. M., Sartor, F., Borrmann, H., Zhuang, X., Naik, A. S., Curtis, A. M., & McKeating, J. A. (2021) · Journal of Biological Rhythms · doi:10.1177/0748730420987669 · Cited by 37
Healy, K., Pin, E., Chen, P., Söderdahl, G., Nowak, P., Mielke, S., Hansson, L., Bergman, P., Smith, C. I. E., Ljungman, P. T., et al. (2022) · Med · doi:10.1016/j.medj.2022.01.001 · Cited by 33
“Notably, people with compromised immunity have been mostly excluded from large clinical trials addressing mRNA vaccine effectiveness.(2,17) Recent published reports have, however, indicated weak or absent immune responses in several groups of immunocompromised persons.”
Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
Caffrey, A. R., Appaneal, H. J., Lopes, V., Puzniak, L., Zasowski, E. J., Jódar, L., LaPlante, K. L., & McLaughlin, J. M. (2024) · Nature Communications · doi:10.1038/s41467-024-53842-w · Cited by 41
Poley, M., Chen, G., Sharf‐Pauker, N., Avital, A., Kaduri, M., Sela, M., Mora‐Raimundo, P., Koren, L., Arber, S., Egorov, E., et al. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200089 · Cited by 42
Mathematical modelling of COVID-19 transmission with optimal control and cost-effectiveness analysis
Ndendya, J. Z., Mlay, G. M., & Rwezaura, H. (2024) · Computer Methods and Programs in Biomedicine Update · doi:10.1016/j.cmpbup.2024.100155 · Cited by 38
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
Kirwin, E. M., Rafferty, E., Harback, K., Round, J. A., & McCabe, C. J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01037-2 · Cited by 37
Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection
Christodoulou, I., Rahnama, R., Ravich, J. W., Seo, J., Zolov, S. N., Marple, A., Markovitz, D. M., & Bonifant, C. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763460 · Cited by 38
“Despite the development and administration of effective vaccines (2, 3), the infection and hospitalization rates due to COVID-19 remain significant, necessitating effective and readily available treatment options.”
BackgroundFrames that matter: Increasing the willingness to get the Covid-19 vaccines
Diament, S. M., Kaya, A., & Magenheim, E. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.114562 · Cited by 42
“Fortunately, the rapid development of highly effective vaccines (Polack et al., 2020; Baden et al., 2020) offers hope for achieving herd immunity and containing the disease’s spread (Haas et al.”
Critical fluctuations in epidemic models explain COVID-19 post-lockdown dynamics
Aguiar, M., Van-Dierdonck, J. B., Mar, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93366-7 · Cited by 38
da Trindade, L. R., da Silva, D. V. T., Baião, D. D. S., & Paschoalin, V. M. F. (2021) · Molecules · doi:10.3390/molecules26154621 · Cited by 42
The dynamics of trust and communication in COVID-19 vaccine decision making: A qualitative inquiry
Ledford, C. J. W., Cafferty, L. A., Moore, J. X., Roberts, C., Whisenant, E. B., Rychtarikova, A. G., & Seehusen, D. A. (2022) · Journal of Health Communication · doi:10.1080/10810730.2022.2028943 · Cited by 39
“In response to the COVID-19 pandemic, scientists coordinated a complex immunization effort that developed and distributed vaccines using old and new technologies by multiple pharmaceutical manufacturers around the world (Baden et al., 2021; Livingston, Malani, & Creech, 2021; Polack et al., 2020).”
BackgroundSARS-CoV-2 variants: biology, pathogenicity, immunity and control
Uraki, R., Korber, B., Diamond, M., & Kawaoka, Y. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01255-x · Cited by 62
“9) (commonly referred to as the Wuhan-1 virus)), and this swift response enabled rapid development of diagnostic tests, vaccines and therapeutics 10,11 .”
The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
Sessa, C., Cortés, J., Conte, P., Cardoso, F., Choueiri, T. K., Dummer, R., LoRusso, P. M., Ottmann, O. G., Ryll, B., Mok, T. S. K., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100339 · Cited by 44
Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans
Cai, M., Xie, Y., & Al‐Aly, Z. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2510226 · Cited by 49
Anderson, R. M., Vegvari, C., Hollingsworth, T. D., Pi, L., Maddren, R., Ng, C. W., & Baggaley, R. F. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0008 · Cited by 45
Benschop, R. J., TUTTLE, J. L., Zhang, L., Poorbaugh, J., Kallewaard, N. L., Vaillancourt, P., Crisp, M., Trinh, T. N. V., Freitas, J. J., Beasley, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3041 · Cited by 38
“Higher antibody titers in individuals who were fully vaccinated with SpikeVax compared with Comirnaty have been reported (34), yet each vaccine has demonstrated more than 90% efficacy in preventing COVID-19 illness (35, 36).”
Baral, P. K., Yin, J., & James, M. N. G. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.013 · Cited by 37
Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era
Xu, C., Lei, C., Hosseinpour, S., Ivanovski, S., Walsh, L. J., & Khademhosseini, A. (2022) · National Science Review · doi:10.1093/nsr/nwac124 · Cited by 43
Psychosocial Factors Predict COVID-19 Vaccine Side Effects
Geers, A. L., Clemens, K. S., Faasse, K., Colagiuri, B., Webster, R., Vase, L., Sieg, M., Jason, E. C., & Colloca, L. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000519853 · Cited by 39
Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults
Erice, A., Varillas‐Delgado, D., & Caballero, C. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.023 · Cited by 40
“The mRNA vaccine BNT162b2 (Pfizer-BioNtech) encoding the receptor binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein has shown 95% efficacy in preventing symptomatic infection in clinical trials [1].”
Milano, E., Ricciardi, A., Casciaro, R., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27629 · Cited by 38
“No patients developed immediate hypersensitivity objective reactions, although, the rate of mild/moderate AEs was collected after the end of complete vaccination and data collection was lower than that reported in other clinical trials.(18,19) This difference was probably due to the different ways in which AE was moni…”
ResultCurrent and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review
Ismail, F. S., Gallus, M., Meuth, S. G., Okada, H., Hartung, H.-P., & Melzer, N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3818 · Cited by 46
Waning immunity and IgG4 responses following bivalent mRNA boosting
Lasrado, N., Collier, A.-R. Y., Miller, J. J., Hachmann, N. P., Liu, J., Anand, T., Bondzie, E. A., Fisher, J. L., Mazurek, C. R., Patio, R. C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj9945 · Cited by 43
Dulfer, E. A., Geckin, B., Taks, E., GeurtsvanKessel, C. H., Dijkstra, H., van Emst, L., Jongh, C. E. V. D. G., van Mourik, D., Koopmans, P. C., Domínguez‐Andrés, J., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100628 · Cited by 36
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Elkrief, A., Wu, J. T.-Y., Jani, C., Enriquez, K. T., Glover, M. J., Shah, M. R., Shaikh, H. G., Beeghly-Fadiel, A. C., French, B. C., Jhawar, S. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1368 · Cited by 39
Wu, K., Xu, F., Dai, Y., Jin, S., Zheng, A., Zhang, N., & Xu, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.007 · Cited by 40
Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Hasegawa, S., Tholany, J., Perencevich, E. N., Maezato, A. M., Ricardo, V. C. V., Salinas, J. L., et al. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.336 · Cited by 41
A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro
Sun, J., Sun, D., Yang, Q., Wang, D., Peng, J., Guo, H., Ding, X., Zhao, C., Yuan, B., Ivanenkov, Y. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59870-4 · Cited by 44
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 45
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
Briggs, F. B. S., Mateen, F. J., Schmidt, H. K., Currie, K. M., Siefers, H. M., Crouthamel, S., Bebo, B. F., Fiol, J., Racke, M. K., O'Connor, K. C., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001104 · Cited by 38
“S, andChAdOx1 nCoV-19 from vaccine trials and observational studies of the general population has been characterized by transient and mild to moderate symptoms, including pain at the injection site, headache, fatigue, fever/ chills, and myalgia.(2,5,9,10) On average, a higher proportion of women, younger adults, and t…”
BackgroundBuilding CRISPR Gene Therapies for the Central Nervous System: A Review
Salomonsson, S. E., & Clelland, C. D. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4983 · Cited by 46
The basis of a more contagious 501Y.V1 variant of SARS-COV-2
Liu, H.-L., Zhang, Q.-Q., Wei, P., et al. (2021) · bioRxiv · doi:10.1101/2021.02.02.428884 · Cited by 2
ACE2‐based decoy receptors for SARS coronavirus 2
Jing, W., & Procko, E. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26140 · Cited by 35
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.